Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In the autumn statement on Wednesday 22 November, the government announced its support for the Rare Therapies Launch Pad, a new programme that will develop regulatory pathways for children with rare conditions to access individualised therapies.

The Oxford-Harrington Rare Disease Centre (OHC) in the Department of Paediatrics has a central role in the delivery of this programme, alongside Genomics England, the Association of the British Pharmaceutical Industry and the Medicines and Healthcare Regulatory Agency.

Tens of millions of children globally, including hundreds of thousands in the UK, have rare and life-threatening genetic diseases, with a very small number having access to a treatment. This announcement offers the prospect of change: new individualised therapeutic options are being created but there is currently no route to access these individualised medicines for most patients. The Launch Pad aims to deliver an end-to-end pathway covering diagnosis, the design and rapid manufacturing of these therapies and treatment.

 

Read the full story at the University of Oxford website.

 

Similar stories

Sixty Seconds with Professor Alan Bernstein

Professor Alan Bernstein is Director of Global Health. The Oxford Global Health initiative brings together researchers from diverse disciplines and showcases the ongoing range of impactful global health research at Oxford. In this Sixty Seconds interview, we hear from Alan about his career to date, his vision for Oxford Global Health, and the lessons he has learnt throughout his career.